Icagen, Inc.'s Phase III Clinical Trial Of ICA-17043 On Course Following Planned Safety Review

Icagen, Inc. (NASDAQ: ICGN) today announced that, following the first per protocol interim safety review, an independent data monitoring committee ("DMC") recommended that Icagen continue its pivotal Phase III clinical trial of ICA-17043 for the treatment of sickle cell disease as planned. The DMC meets approximately every six months to review unblinded safety data from the pivotal Phase III clinical trial.

Back to news